137 related articles for article (PubMed ID: 35795617)
1. Diagnostic Value of Magnetic Resonance Susceptibility-Weighted Imaging Scanning in Different Types of Early Prostate Cancer.
Gao R; Liu J; Zhu H
Scanning; 2022; 2022():4884646. PubMed ID: 35795617
[TBL] [Abstract][Full Text] [Related]
2. [The value of DISCO and MUSE-DWI combined with prostate specific antigen density in the diagnosis and risk stratification of prostate cancer].
Chen ZQ; Zhang D; Wang Z; Song N; Ma AL; Zhang SR; Cai L
Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1461-1468. PubMed ID: 37198108
[No Abstract] [Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Optimized Fast Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate: Effect of Sampling Duration on Pharmacokinetic Parameters.
Othman AE; Falkner F; Martirosian P; Schraml C; Schwentner C; Nickel D; Nikolaou K; Notohamiprodjo M
Invest Radiol; 2016 Feb; 51(2):106-12. PubMed ID: 26447494
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
[No Abstract] [Full Text] [Related]
6. The Utility of Diffusion-Weighted Imaging and Perfusion Magnetic Resonance Imaging Parameters for Detecting Clinically Significant Prostate Cancer.
Cindil E; Oner Y; Sendur HN; Ozdemir H; Gazel E; Tunc L; Cerit MN
Can Assoc Radiol J; 2019 Nov; 70(4):441-451. PubMed ID: 31561925
[TBL] [Abstract][Full Text] [Related]
7. DCE-MRI and DWI can differentiate benign from malignant prostate tumors when serum PSA is ≥10 ng/ml.
Sun H; Du F; Liu Y; Li Q; Liu X; Wang T
Front Oncol; 2022; 12():925186. PubMed ID: 36578948
[TBL] [Abstract][Full Text] [Related]
8. [The value of relaxation time quantitative technique from synthetic magnetic resonance imaging in the diagnosis and invasion assessment of prostate cancer].
Song N; Wang T; Zhang D; Wang Z; Zhang SR; Yu J; Cai L; Ma AL; Zhang Q; Chen ZQ
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(15):1093-1099. PubMed ID: 35436808
[No Abstract] [Full Text] [Related]
9. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
10. Prostate Cancer Screening with Magnetic Resonance Imaging: Results from the Second Round of the Göteborg Prostate Cancer Screening 2 Trial.
Wallström J; Geterud K; Kohestani K; Maier SE; Pihl CG; Socratous A; Stranne J; Arnsrud-Godtman R; Månsson M; Hellström M; Hugosson J
Eur Urol Oncol; 2022 Feb; 5(1):54-60. PubMed ID: 34580053
[TBL] [Abstract][Full Text] [Related]
11. Combining Magnetic Resonance Diffusion-Weighted Imaging with Prostate-Specific Antigen to Differentiate Between Malignant and Benign Prostate Lesions.
Han L; He G; Mei Y; Yu Q; Zhao M; Luo F; Cheng G; Liang W
Med Sci Monit; 2022 Apr; 28():e935307. PubMed ID: 35459760
[TBL] [Abstract][Full Text] [Related]
12. Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis in Biopsy-naive Men with Suspected Prostate Cancer Based on Elevated Prostate-specific Antigen Values: Results from a Randomized Prospective Blinded Controlled Trial.
Tonttila PP; Lantto J; Pääkkö E; Piippo U; Kauppila S; Lammentausta E; Ohtonen P; Vaarala MH
Eur Urol; 2016 Mar; 69(3):419-25. PubMed ID: 26033153
[TBL] [Abstract][Full Text] [Related]
13. Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography: The IP1-PROSTAGRAM Study.
Eldred-Evans D; Burak P; Connor MJ; Day E; Evans M; Fiorentino F; Gammon M; Hosking-Jervis F; Klimowska-Nassar N; McGuire W; Padhani AR; Prevost AT; Price D; Sokhi H; Tam H; Winkler M; Ahmed HU
JAMA Oncol; 2021 Mar; 7(3):395-402. PubMed ID: 33570542
[TBL] [Abstract][Full Text] [Related]
14. Clinical Value of Magnetic Resonance Imaging Combined With Serum Prostate-specific Antigen, Epithelial Cadherin and Early Prostate Cancer Antigen 2 In Diagnosis of Prostate Cancer.
Li K; Luan Q; Zheng J; Li R; Li L; Sun Y; Liu D
Anticancer Res; 2023 Jan; 43(1):441-447. PubMed ID: 36585192
[TBL] [Abstract][Full Text] [Related]
15. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
[TBL] [Abstract][Full Text] [Related]
16. Comparison of different population-averaged arterial-input-functions in dynamic contrast-enhanced MRI of the prostate: Effects on pharmacokinetic parameters and their diagnostic performance.
Othman AE; Falkner F; Kessler DE; Martirosian P; Weiss J; Kruck S; Kaufmann S; Grimm R; Kramer U; Nikolaou K; Notohamiprodjo M
Magn Reson Imaging; 2016 May; 34(4):496-501. PubMed ID: 26708031
[TBL] [Abstract][Full Text] [Related]
17. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies.
Rais-Bahrami S; Siddiqui MM; Vourganti S; Turkbey B; Rastinehad AR; Stamatakis L; Truong H; Walton-Diaz A; Hoang AN; Nix JW; Merino MJ; Wood BJ; Simon RM; Choyke PL; Pinto PA
BJU Int; 2015 Mar; 115(3):381-8. PubMed ID: 24447678
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
20. Effect of Temporal Resolution on Diagnostic Performance of Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Prostate.
Othman AE; Falkner F; Weiss J; Kruck S; Grimm R; Martirosian P; Nikolaou K; Notohamiprodjo M
Invest Radiol; 2016 May; 51(5):290-6. PubMed ID: 26619282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
